Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Osteoclasts are specialized multinucleated cells derived from the monocyte-macrophage lineage that are responsible for the degradation of mineralized bone matrix [1]. The bone-resorbing machinery of these cells is a critical therapeutic target in the management of osteoradionecrosis (ORN) and other metabolic bone diseases [2]. In the PENTOCLO protocol, clodronate or substituted bisphosphonates are utilized to inhibit this machinery and induce osteoclast apoptosis, thereby halting pathological bone resorption [3]. Clodronate specifically acts as a pro-drug that is converted into cytotoxic ATP metabolites within the cell, while nitrogenous bisphosphonates interfere with the mevalonate pathway [1][5]. This targeted approach, when combined with the antioxidant effects of tocopherol and the anti-fibrotic properties of pentoxifylline, promotes the healing of radiation-damaged bone tissue [2][4]. Understanding this target is essential for optimizing treatments that address the complex interplay of vascular insufficiency and bone turnover in necrotic bone conditions [4]. References: [1] Rogers MJ, et al. Bone. 2011; [2] Delanian S, et al. Radiation Oncology. 2011; [3] Frith JC, et al. JBMR. 1997; [4] Lyons A, et al. Br J Oral Maxillofac Surg. 2015; [5] Russell RG. Pediatrics. 2007.
Clodronate is a non-nitrogenous bisphosphonate that is metabolized by osteoclasts into non-hydrolyzable ATP analogs (adenosine 5'-(beta,gamma-dichloromethylene) triphosphate), which inhibit mitochondrial adenine nucleotide translocase (ANT), leading to osteoclast apoptosis [1][3]. Substituted nitrogenous bisphosphonates, which may be used in modified PENTOCLO protocols, inhibit farnesyl pyrophosphate synthase (FPPS) in the mevalonate pathway, preventing the prenylation of small GTPases (e.g., Rho, Rac, Rab) essential for the formation of the ruffled border and osteoclast survival [1][5].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Osteoclast bone-resorbing machinery.